R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia
- Samsara BioCapital, a leading biotech investor active across private and public markets, joins global investor syndicate
- Funds will be used to advance AP306, a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for hyperphosphatemia in patients on dialysis
- Investment comes ahead of Phase 2b topline data, expected in H1 2027
Redwood City, California – 30 September 2026 – R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company developing first-in-class therapies for patients with kidney disease, today announced an expansion of its Series A financing to $80.5 million, with new investment from Samsara BioCapital.
